Naveen Pemmaraju: Prognostic Impact of NPM1 Co-Mutation in FLT3-Mutated AML
Naveen Pemmaraju, Director of Leukemia-Cancer Network, Executive Director of Cancer Medicine, Director of BPDCN at the Department of Leukemia, and Professor at the Department of Leukemia at MD Anderson Cancer Center, shared a post on X about a paper he co-authored with colleagues published in Cancer:
“Important new paper led by Dr. Sankalp Arora and Naval Daver just out in ACS Journal Cancer.
FLT3TKD NPM1 for patients with AML.”
Title: Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutation
Authors: Sankalp Arora, Wei-Ying Jen, Musa Yilmaz, Indraneel Deshmukh, Jayastu Senapati, Sanam Loghavi, Ghayas C. Issa, Nicholas J. Short, Tapan M. Kadia, Courtney D. DiNardo, Gautam Borthakur, Joseph Jabbour, Naveen Pemmaraju, Michael Andreeff, Koichi Takahashi, Kapil Bhalla, Uday Popat, Elizabeth J. Shpall, Betul Oran, Hussein A. Abbas, Guillermo Garcia-Manero, Farhad Ravandi, Hagop Kantarjian, Naval Daver
You can read the Full Article on Cancer.
More posts featuring Naveen Pemmaraju.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023